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SUMMARY: The prevalence of ceftriaxone resistance and the associated genes encoding extended-spec-
trum b-lactamase (ESBL) was determined in 149 non-duplicate non-typhoidal Salmonella isolated in
2008–2009 from patients in a tertiary care hospital in Kuala Lumpur, Malaysia. The resistance rate to
ceftriaxone was 2.7z (2/74) in 2008, 4.0z (3/75) in 2009, and 3.4z (5/149) overall. CTX-M ESBL
genes were detected in 2 of the 5 ceftriaxone-resistant isolates. The prevalence of ceftriaxone resistance,
although low, is a concern because it limits therapeutic options. Continued surveillance of ceftriaxone
resistance is important to monitor its trends
Ceftriaxone is one of the most commonly used an-
tibiotics for treatment of invasive infections with
non-typhoidal Salmonella spp. (1). Ceftriaxone resis-
tance among Salmonella spp., however, has been
reported worldwide (2–13), and common resistance
mechanisms include the production of plasmid-mediat-
ed AmpC b-lactamases and extended-spectrum b-lac-
tamases (ESBLs) (2–5,7–9). A previous study involving
78 clinical isolates of Salmonella spp. from our hospital
(2007–2008) showed that the ceftriaxone resistance rate
was 1.3z and detected only 1 ceftriaxone-resistant
(CRO-R) isolate (Salmonella Enteritidis); a putative
ESBL producer was detected by the double-disk diffu-
sion method, but the mechanism of resistance was not
elucidated (11). A study from a different hospital in
northern Malaysia (12) that included 80 Salmonella iso-
lates from January 2005 to June 2006 estimated a
ceftriaxone resistance rate of 6.3z among all isolates
and 3.2z among invasive extra-intestinal isolates with
the disk-diffusion method. On the other hand, the Na-
tional Surveillance of Antimicrobial Resistance Report
from the Ministry of Health, Malaysia (for 2009) (13),
using data from 16 Malaysian hospitals (not including
our hospital), reported a ceftriaxone resistance rate of
2.4z among Salmonella spp. This study aimed to deter-
mine the prevalence of ceftriaxone resistance among
non-typhoidal Salmonella spp. (which in this study
refers to all Salmonella spp., except S. Typhi and S.
Paratyphi A, B, and C, and hereinafter referred to as
NTS) isolated from patients admitted to the University
of Malaya Medical Centre (UMMC) between January
2008 and December 2009, and to identify ESBL genes
among such isolates.
All non-duplicate NTS (previously identified by stan-
dard biochemical tests and Salmonella antisera by the
Diagnostic Microbiology Laboratory, UMMC) stocked
during the study period were included. Only 1 isolate
per patient was included, except in the case of 3 patients
where a subsequent isolate was also included because it
belonged to a different serogroup. If an NTS was isolat-
ed from both blood and another site of a patient, only
the blood isolate was included, except in 2 cases where
the blood isolate was unavailable. The minimum inhibi-
tory concentration (MIC) of ceftriaxone was determined
by Etest (AB bioM áerieux, Solna, Sweden) and interpret-
ed according to the Clinical Laboratory Standards In-
stitute (CLSI) 2010 guidelines (sensitive, Ã1 mg/ml;
resistant, Æ4 mg/ml) (14). CRO-R isolates were recon-
firmed as Salmonella spp. with the API 20E system
(bioM áerieux SA, Marcy l'Etoile, France), and their sen-
sitivities to other antimicrobials previously performed in
the laboratory according to the CLSI guidelines (15),
were retrieved from laboratory records. ESBL genes
(blaCTX-M, blaSHV, and blaTEM) among CRO-R isolates
were detected using previously published PCR primers
and methods (16,17); the primers used were MA-1
(5?-SCS ATG TGC AGY ACC AGT AA-3?) and MA-2
(5?-CCG CRA TAT GRT TGG TGG TG-3?) for bla
CTX-M, OS-5 (5?-TTA TCT CCC TGT TAG CCA
CC-3?) and OS-6 (5?-GAT TTG CTG ATT TCG CTC
GG-3?) for blaSHV, and C (5?-TCG GGG AAA TGT
GCG CG-3?) and D (5?-TGC TTA ATC AGT GAG
GCA CC-3?) for blaTEM (16,17). To characterize the
CTX-M genes, we carried out PCR amplification as
previously described (18) with primers ISEcp1 U1
(5?-AAA AAT GAT TGA AAG GTG GT-3?) and P2D
(5?-CAG CGC TTT TGC CGT CTA AG-3?). The PCR
products were purified with the GeneAll PCR SV kit
(General Biosystem, Seoul, Korea), and the subsequent
sequencing reaction was performed with the Big Dye}
Terminator V3.1 Cycle Sequencing Kit (Applied
2Table 1. Source of NTS and ceftriaxone resistant NTS isolates (2008–2009)
Year
No. CRO-R/no. of NTS (z) MIC50
(mg/ml)
MIC90
(mg/ml)Blood Stool Others Total
2009 (n＝ 75) 2/21 (9.52) 1/53 (1.89) 0/11) (0) 3/75 (4.00) 0.125 0.125
2008 (n＝ 74) 0/12 (0) 2/62 (3.23) 0/0 (—) 2/74 (2.70) 0.094 0.125
Total (n＝ 149) 2/33 (6.10) 3/115 (2.61) 0/1 (0) 5/149 (3.36) 0.094 0.125
1): urine.
NTS, non-typhoidal Salmonella spp. except S. Typhi and S. Paratyphi A, B, and C; CRO-R, ceftriaxone
resistant.
Table 2. Source, MIC of ceftriaxone, b-lactamase gene detected, and susceptibility to other antimicrobials determined by disk diffusion for
the 5 ceftriaxone-resistant isolates
Isolate no.
(year) Source Identification
MIC of CRO
(mg/ml)
ESBL gene
detected
Other b-lactamase
genes detected
Susceptibility to other
antimicrobials by disk diffusion
1 (2008) Stool S. Typhimurium 24 (R) — TEM-1 S＝ IPM; I＝ CIP;
R＝ AMP, SXT, Tet, CHL, NA
2 (2008) Stoo Salmonella spp.
(serogroup E)
256 (R) — — S＝ SXT, CIP, Tet, CHL, NA;
R＝ AMP
3 (2009) Blood S. Enteritidis Æ256 (R) CTX-M-14-like — S＝ CHL, CIP, NA, IPM;
R＝ AMP, SXT, Tet
4 (2009) Stool S. Typhimurium 32 (R) — — S＝ SXT, CIP, Tet, CHL, NA;
R＝ AMP
5 (2009) Blood Salmonella spp.
(serogroup C1)
Æ256 (R) CTX-M-55/57 TEM-1 S＝ CIP, CHL, NA, IPM;
R＝ AMP, SXT, Tet
R, resistant; S, sensitive; I, intermediate; CRO, ceftriaxone; CIP, ciprofloxacin; CHL, chloramphenicol; Tet, tetracycline; Amp, ampicillin;
SXT, trimethoprim-sulfamethoxazole; NA, nalidixic acid; IPM, imipenem.
Biosystems, Foster City, Calif., USA) on an ABI-377
Genetic Analyzer (Applied Biosystems), using forward
and reverse primers. The sequences obtained were used
for a BLAST search in the GenBank database. Suscepti-
bility to cefoxitin for the CRO-R isolates by the CLSI
disk-diffusion method (14) was also determined.
A total of 149 non-duplicate isolates was available for
the study (75 from 2009 and 74 from 2008) (Table 1).
Two more isolates recorded in the stock culture collec-
tion for 2008 were excluded, because they were not
retrievable for MIC testing (laboratory records showed
sensitivity to ceftriaxone by disk diffusion). The MIC50
and MIC90 of the 149 isolates were 0.094 mg/ml and
0.125 mg/ml, respectively (Table 1). Five CRO-R NTS
were detected in the study collection, and ESBL genes
were detected in 2 of them. None of the isolates had an
intermediate MIC. The resistance rate to ceftriaxone
was 2.7z (2/74) in 2008, 4.0z (3/75) in 2009, and
3.4z (5/149) overall (Table 1). The frequency of
ceftriaxone resistance among our isolates was low but is
still a concern because it limits therapeutic options, and
the detection of ESBL genes further raises the possibili-
ty of spread as many of these genes are expressed in
plasmids (2,3,7,9), although they may also be found in
the chromosome (19). In the United States, the
ceftriaxone resistance rate among non-typhoidal
Salmonella as reported by the National Antimicrobial
Resistance Monitoring System (20) was 2.9z in 2008,
whereas this rate was 3.3z and 3.7z in 2007 and 2006,
respectively, using the revised CLSI MIC breakpoint of
Æ4 mg/ml (14). A study in Taiwan (7) showed that be-
tween January 1999 and December 2002, only 1.02z of
non-typhoidal Salmonella isolates were resistant to
ceftriaxone. On the other hand, a multinational study
(10) involving randomly collected non-typhoid isolates
during 2003 to 2005 from 7 Asian countries (not includ-
ing Malaysia) showed that reduced susceptibility to
ceftriaxone (defined in that study as MIC＝ 2–8 mg/ml)
was uncommon in Asian countries, except Taiwan
(38z), and was not observed in S. Typhimurium (25z)
in all countries. It also reported that a ceftriaxone
resistance rate of 3.0z, compared with 10.8z in
Taiwan (10). When comparing ceftriaxone resistance
rates, the criteria used for interpretation as ``resistant''
should be noted because the CLSI published revised
ceftriaxone breakpoints in 2010 (14).
In the present study, isolate Nos. 3 and 5 were cefoxi-
tin sensitive, whereas isolate Nos. 1, 2, and 4 were
cefoxitin resistant. ESBL genes were detected in 2
(isolate Nos. 3 and 5) out of 5 (40z) CRO-R isolates.
Sequence analysis of the 476-bp amplicons suggested
100z identity of the genes to those of blaCTX-M-15 and
blaCTX-M-14, respectively. Further, PCR revealed that iso-
late No. 5 had the partial ISEcp1 element located in the
upstream region, and sequencing of the 876-bp ampli-
con identified the CTX-M gene as blaCTX-M-55/57. This
isolate also had a TEM-1 gene (Table 2). The ISEcp1
element was not detected in isolate No. 3. The CTX-M
genes identified in this study have been previously found
among Salmonella spp. (7,9,21), and other mechanisms
or rarer ESBL genes may have been responsible for the
cefoxitin resistance of 3 other CRO-R isolates (isolates
Nos. 1, 2, and 4). There are no CLSI guidelines for the
detection of AmpC-mediated resistance at present.
Resistance to cefoxitin indicates that the resistance may
be AmpC-mediated, but it can also indicate reduced
outer membrane permeability or the presence of certain
carbapenemases (22,23). Therefore, further phenotypic
3and molecular tests (23) should be performed to confirm
the type of resistance to ceftriaxone in the 3 other
isolates.
In a study in Singapore (8), among 15 isolates of
Salmonella spp. with diminished susceptibility to
ceftriaxone, obtained in 2003–2006, 9 were found to ex-
press ESBL genes and 6 were found to express plasmid
AmpC genes; the ESBL genes detected were blaSHV-5,
blaCTX-M group 1, and blaCTX-M group 9.
In summary, we report the prevalence of ceftriaxone
resistance (3.4z) among 149 non-duplicate NTS from
the UMMC over a 2-year period from January 2008 to
December 2009. Two of the 5 CRO-R isolates in this
study expressed CTX-M ESBL genes. Continued sur-
veillance of ceftriaxone resistance using standardized
criteria is necessary to monitor its trends.
Acknowledgments This study was supported by a University of
Malaya Research Grant: RG067/09HTM.
We would like to thank Chan Chui Lin for technical help rendered.
Part of this study was presented as a poster at the 12th Western
Pacific Congress on Chemotherapy and Infectious Diseases (Decem-
ber 2–5, 2010, Singapore) and was included in the CD of abstracts
from this conference.
Conflict of interest None to declare.
REFERENCES
1. Pegues, D.A. and Miller, S.I. (2010): Salmonellosis. p. 521–530.
In D.L. Kasper and A.S. Fauci (ed.), Harrison's Infectious Dis-
eases. McGraw-Hill Companies, Inc.
2. Vahaboglu, H., Hall, L.M., Mulazimoglu, L., et al. (1995):
Resistance to extended-spectrum cephalosporins, caused by
PER-1 beta-lactamase, in Salmonella typhimurium from Istan-
bul, Turkey. J. Med. Microbiol., 43, 294–299.
3. Tassios, P.T., Gazouli, M., Tzelepi, E., et al. (1999): Spread of a
Salmonella typhimurium clone resistant to expanded-spectrum
cephalosporins in three European countries. J. Clin. Microbiol.,
37, 3774–3777.
4. Dunne, E.F., Fey, P.D., Kludt, P., et al. (2000): Emergence of
domestically acquired ceftriaxone-resistant Salmonella infections
associated with AmpC beta-lactamase. JAMA, 284, 3151–3156.
5. Yan, J.J., Ko, W.C., Chiu, C.H., et al. (2003): Emergence of
ceftriaxone-resistant Salmonella isolates and rapid spread of plas-
mid-encoded CMY-2-like cephalosporinase, Taiwan. Emerg. In-
fect. Dis., 9, 323–328.
6. Benacer, D., Thong, K.L., Watanabe, H., et al. (2010): Charac-
terization of drug resistant Salmonella enterica serotype
Typhimurium by antibiograms, plasmids, integrons, resistance
genes and PFGE. J. Microbiol. Biotechnol., 20, 1042–1052.
7. Li, W.C., Huang, F.Y., Liu, C.P., et al. (2005): Ceftriaxone
resistance of nontyphoidal Salmonella enterica isolates in north-
ern Taiwan attributable to production of CTX-M-14 and CMY-2
beta-lactamases. J. Clin. Microbiol., 43, 3237–3243.
8. Koh, T.H., Koh, A.E., Hamdan, A., et al. (2008): Ceftriaxone-
resistant Salmonella spp. in Singapore. Ann. Acad. Med. Singa-
pore, 37, 900–901.
9. Hopkins, K.L., Threlfall, E.J., Karisik, E., et al. (2008): Identifi-
cation of novel plasmid-mediated extended-spectrum beta-lac-
tamase CTX-M-57 in Salmonella enterica serovar Typhimurium.
Int. J. Antimicrob. Agents, 31, 85–86.
10. Lee, H.Y., Su, L.H., Tsai, M.H., et al. (2009): High rate of
reduced susceptibility to ciprofloxacin and ceftriaxone among
nontyphoid Salmonella clinical isolates in Asia. Antimicrob.
Agents Chemother., 53, 2696–2699.
11. Tiong, V., Thong, K.L., Yusof, M.Y.M., et al. (2010): Macrores-
triction analysis and antimicrobial susceptibility profiling of
Salmonella enterica at a university teaching hospital, Kuala Lum-
pur. Jpn. J. Infect. Dis., 63, 317–322.
12. Thong, K.L., Lai, W.L. and Dhanoa, A. (2011): Antimicrobial
susceptibility and pulsed-field gel electrophoretic analysis of
Salmonella in a tertiary hospital in northern Malaysia. J. Infect.
Public Health, 4, 65–72. doi:10.1016/j.jiph.2011.03.003.
13. Ministry of Health, Malaysia (2009): National Surveillance of An-
tibiotic Resistance Report. Ministry of Health, Malaysia 2009.
Online at 〈http://www.imr.gov.my/report/Summaryz20ofz
20antibioticz20resistancez202009z20forz20website.pdf〉.
14. Clinical and Laboratory Standards Institute (CLSI) (2010): Per-
formance standards for antimicrobial susceptibility testing; 18th
Informational Supplement. CLSI document M100-S20. Wayne,
Pa.
15. Clinical and Laboratory Standards Institute (CLSI) (2008): Per-
formance standards for antimicrobial susceptibility testing; 19th
informational supplement. CLSI document M100-S18. Wayne,
Pa.
16. Cao, V., Lambert, T. and Courvalin, P. (2002): ColE1-like plas-
mid pIP843 of Klebsiella pneumoniae encoding extended-spec-
trum b-lactamase CTX-M-17. Antimicrob. Agents Chemother.,
46, 1212–1217.
17. Rotimi, V.O., Jamal, W., Pal, T., et al. (2008): Emergence of
CTX-M-15 extended-spectrum beta-lactamase-producing Salmo-
nella spp. in Kuwait and the United Arab Emirates. J. Med.
Microbiol., 57, 881–886.
18. Munday, C.J., Xiong, J., Li, C., et al. (2004): Dissemination of
CTX-M type beta-lactamases in Enterobacteriaceae isolates in the
People's Republic of China. Int. J. Antimicrob. Agents, 23,
175–180.
19. Rodráƒguez, M.M., Power, P., Radice, M., et al. (2004): Chro-
mosome-encoded CTX-M-3 from Kluyvera ascorbata: a possible
origin of plasmid-borne CTX-M-1 derived cefotaximases. An-
timicrob. Agents Chemother., 48, 4895–4897.
20. Centers for Disease, Control and Prevention (CDC) (2010): Na-
tional Antimicrobial Resistance Monitoring System for Enteric
Bacteria (NARMS): Human Isolates Final Report, 2008. U.S.
Department of Health and Human Services, CDC, Atlanta, Ga.
21. Sj äolund-Karlsson, M., Howie, R., Krueger, A., et al. (2011):
CTX-M-producing non-typhi Salmonella spp. isolated from hu-
mans, United States. Emerg. Infect. Dis., 17, 97–99.
22. Pai, H., Kang C.-I., Byeon, J.-H., et al. (2004): Epidemiology
and clinical features of bloodstream infections caused by AmpC-
type-b-lactamase-producing Klebsiella pneumoniae. Antimicrob.
Agents Chemother., 48, 3720–3728.
23. Jacoby, G.A. (2009): AmpC b-lactamases. Clin. Microbiol. Rev.,
22, 161–182.
